337 related articles for article (PubMed ID: 15456957)
1. Subtype selective interactions of somatostatin and somatostatin analogs with sst1, sst2, and sst5 in BON-1 cells.
Ludvigsen E; Stridsberg M; Taylor JE; Culler MD; Oberg K; Janson ET
Med Oncol; 2004; 21(3):285-95. PubMed ID: 15456957
[TBL] [Abstract][Full Text] [Related]
2. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
[TBL] [Abstract][Full Text] [Related]
3. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
[TBL] [Abstract][Full Text] [Related]
5. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures.
Djordjijevic D; Zhang J; Priam M; Viollet C; Gourdji D; Kordon C; Epelbaum J
Endocrinology; 1998 May; 139(5):2272-7. PubMed ID: 9564833
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
7. Dopamine receptor subtype 2 and somatostatin receptor subtype 5 expression influences somatostatin analogs effects on human somatotroph pituitary adenomas in vitro.
Zatelli MC; Piccin D; Tagliati F; Bottoni A; Ambrosio MR; Margutti A; Scanarini M; Bondanelli M; Culler MD; degli Uberti EC
J Mol Endocrinol; 2005 Oct; 35(2):333-41. PubMed ID: 16216913
[TBL] [Abstract][Full Text] [Related]
8. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
[TBL] [Abstract][Full Text] [Related]
9. Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization.
Durán-Prado M; Bucharles C; Gonzalez BJ; Vázquez-Martínez R; Martínez-Fuentes AJ; García-Navarro S; Rhodes SJ; Vaudry H; Malagón MM; Castaño JP
Endocrinology; 2007 Jan; 148(1):411-21. PubMed ID: 17053026
[TBL] [Abstract][Full Text] [Related]
10. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors.
Hofland LJ; De Herder WW; Visser-Wisselaar HA; Van Uffelen C; Waaijers M; Zuyderwijk J; Uitterlinden P; Kros MJ; Van Koetsveld PM; Lamberts SW
J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735
[TBL] [Abstract][Full Text] [Related]
11. Somatostatin receptor subtypes sst1, sst2, sst3 and sst5 expression in human pituitary, gastroentero-pancreatic and mammary tumors: comparison of mRNA analysis with receptor autoradiography.
Schaer JC; Waser B; Mengod G; Reubi JC
Int J Cancer; 1997 Mar; 70(5):530-7. PubMed ID: 9052751
[TBL] [Abstract][Full Text] [Related]
12. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
13. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors.
Schmid HA; Schoeffter P
Neuroendocrinology; 2004; 80 Suppl 1():47-50. PubMed ID: 15477717
[TBL] [Abstract][Full Text] [Related]
14. Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitro.
Ibáñez-Costa A; Rivero-Cortés E; Vázquez-Borrego MC; Gahete MD; Jiménez-Reina L; Venegas-Moreno E; de la Riva A; Arráez MÁ; González-Molero I; Schmid HA; Maraver-Selfa S; Gavilán-Villarejo I; García-Arnés JA; Japón MA; Soto-Moreno A; Gálvez MA; Luque RM; Castaño JP
J Endocrinol; 2016 Nov; 231(2):135-145. PubMed ID: 27587848
[TBL] [Abstract][Full Text] [Related]
15. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
Zatelli MC; Piccin D; Bottoni A; Ambrosio MR; Margutti A; Padovani R; Scanarini M; Taylor JE; Culler MD; Cavazzini L; degli Uberti EC
J Clin Endocrinol Metab; 2004 Oct; 89(10):5181-8. PubMed ID: 15472224
[TBL] [Abstract][Full Text] [Related]
16. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
[TBL] [Abstract][Full Text] [Related]
17. Antisecretory Effects of Chimeric Somatostatin/Dopamine Receptor Ligands on Gastroenteropancreatic Neuroendocrine Tumors.
Couvelard A; Pélaprat D; Dokmak S; Sauvanet A; Voisin T; Couvineau A; Ruszniewski P
Pancreas; 2017; 46(5):631-638. PubMed ID: 28375946
[TBL] [Abstract][Full Text] [Related]
18. Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.
Zatelli MC; Tagliati F; Piccin D; Taylor JE; Culler MD; Bondanelli M; degli Uberti EC
Biochem Biophys Res Commun; 2002 Oct; 297(4):828-34. PubMed ID: 12359227
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
